CEFTAZ-500
Description
- Contains Ceftriaxone 500 mg and Tazobactam 62.5 mg for enhanced antibacterial action
- Broad-spectrum coverage against resistant Gram-positive and Gram-negative bacteria
- Effective in treating serious infections: respiratory, urinary, abdominal, and skin infections
- Tazobactam inhibits beta-lactamase enzymes, protecting Ceftriaxone from degradation
- Administered via intravenous or intramuscular injection for rapid action
- Ideal for hospital or clinical use under physician guidance
Composition
Ceftriaxone 500 mg + Tazobactam 62.5 mg
Benefits
CEFTAZ-562.50 offers broad-spectrum antibacterial coverage, making it highly effective against a wide range of Gram-positive and Gram-negative organisms, including beta-lactamase producing strains. The addition of Tazobactam extends the antibiotic spectrum of Ceftriaxone, allowing for successful treatment of resistant infections. It is especially beneficial in hospitalized patients or those with complicated infections requiring parenteral therapy. CEFTAZ-562.50 delivers fast bacterial eradication, reduces infection-related symptoms, and supports quicker recovery when administered under appropriate medical supervision.
Introduction
CEFTAZ-562.50 is a powerful injectable antibiotic formulation combining Ceftriaxone, a third-generation cephalosporin, with Tazobactam, a beta-lactamase inhibitor. This synergistic combination enhances the antibacterial activity of Ceftriaxone by protecting it from degradation by beta-lactamase enzymes produced by resistant bacteria. CEFTAZ-562.50 is indicated for the treatment of moderate to severe bacterial infections, including those of the respiratory tract, urinary tract, intra-abdominal region, skin and soft tissues, and gynecological infections.
